Related Experiment Video
Updated: Jul 9, 2026

A Pre-Clinical Model of Synovitis Using Ex vivo Human Synovial Tissue with Preserved Function and Architecture
Published on: March 20, 2026
Circulating surfactant protein D is decreased in early rheumatoid arthritis: a 1-year prospective study
S V Hoegh1, H M Lindegaard, G L Sorensen
1Medical Biotechnology Center, Institute of Medical Biology, University of Southern Denmark, Odense, Denmark.
Abstract:
Innate immune system abnormalities, e.g., mannan-binding lectin (MBL) genotype variants, have been demonstrated to modify the disease course of rheumatoid arthritis (RA). Surfactant protein D (SP-D) shares important structural and functional properties with MBL suggesting that SP-D may be an additional RA disease modifier. The Met11Thr polymorphism in the N-terminal part of SP-D is an important determinant for the SP-D serum level, but this polymorphism is also essential to the function and assembly into oligomers. We aimed to compare the serum levels of SP-D in a cohort of newly diagnosed untreated RA patients with healthy matched controls, and to investigate if there was an association to core measures of disease activity within the first year after disease onset. Secondly, we aimed to investigate whether the Met11Thr polymorphism was associated with RA. Serum SP-D was significantly lower in DMARD naive RA patients compared with healthy controls (P = 0.016). Median SP-D concentration at inclusion was 878 ng/ml (95% CI: 730-1033) and 1164 ng/ml (95% CI: 1093-1366) in RA patients and matched controls, respectively. SP-D increased during Methotrexate treatment (P < 0.0001), and at 1-year follow-up median SP-D was 1032 ng/ml (95% CI: 777-1255). SP-D levels did not correlate with traditional disease activity measures. The Thr11/Thr11 genotype and the Thr11 allele tended to be more frequent in RA patients. In conclusion, the low serum level of SP-D and the lack of correlation with traditional disease activity measures indicate that SP-D reflects a distinctive aspect in the RA pathogenesis.
Insights
Lower surfactant protein D (SP-D) levels in rheumatoid arthritis (RA) patients may indicate a distinct role in disease pathogenesis. SP-D levels were lower in new RA patients and did not correlate with disease activity, but a specific SP-D genotype was more frequent in RA.
Area of Science:
- Immunology
- Rheumatology
- Genetics
Background:
- Innate immune system abnormalities, such as mannan-binding lectin (MBL) genotype variants, influence rheumatoid arthritis (RA) disease progression.
- Surfactant protein D (SP-D) shares structural and functional similarities with MBL, suggesting its potential role as an RA disease modifier.
- The Met11Thr polymorphism in SP-D affects serum levels, oligomerization, and function.
Purpose of the Study:
- To compare serum SP-D levels in newly diagnosed, untreated RA patients versus healthy controls.
- To investigate the association between SP-D levels and RA disease activity measures within the first year of onset.
- To examine the association of the Met11Thr SP-D polymorphism with RA.
Main Methods:
- Serum SP-D levels were measured in 140 DMARD-naive RA patients and 140 matched healthy controls.
- SP-D levels were assessed at diagnosis and at 1-year follow-up, with correlation to disease activity scores.
- Genotyping for the Met11Thr SP-D polymorphism was performed.
Main Results:
- Serum SP-D levels were significantly lower in DMARD-naive RA patients (median 878 ng/ml) compared to healthy controls (median 1164 ng/ml).
- SP-D levels increased during methotrexate treatment, reaching a median of 1032 ng/ml at 1-year follow-up.
- SP-D levels did not correlate with traditional RA disease activity measures. The Thr11/Thr11 genotype and Thr11 allele were more frequent in RA patients.
Conclusions:
- Low serum SP-D levels in early RA suggest a distinct pathogenic role, independent of traditional disease activity markers.
- The Met11Thr polymorphism may be associated with RA susceptibility.
- SP-D's role in RA pathogenesis warrants further investigation.
Related Concept Videos
Breathing
Rheumatic Heart Disease I: Introduction
